SMITH: “A change for FDA approved marijuana products and all other marijuana products through medical marijuana licenses in states that allow the drug for medicinal purposes. Those drugs now classified as schedule 3 proponents say this is a good change because marijuana shouldn’t be considered a schedule. One drug like heroin. The difference schedule one is a drug considered to have no accepted medical purposes. Schedule. 3 drugs are deemed to have moderate to low potential for physical and psychological dependence. The Ohio cannabis coalition supports the move. In a statement from executive director David boling, he calls this important progress in federal policy and says it brings long overdue tax relief for Ohio businesses.”

FindClipsBankNewsBaseRadioBankPodBankTranscriptBankPhotoBankPrintBankClipLiveClipperNewsClipperTVClipperWebClipperRadioClipperPodClipperGifCreatorNewsMonitorCityMonitorShareUploadGifsGalleryLiveShareShowCasterAboutNewsHow-ToRSSLoginRegisterNewsListsClips

DOJ Officially Reclassifies Marijuana as Less Dangerous Drug‘Schedule 3 drugs are deemed to have moderate to low potential for physical and psychological dependence’News & PoliticsRUSH EXCERPT:SMITH: “A change for FDA approved marijuana products and all other marijuana products through medical marijuana licenses in states that allow the drug for medicinal purposes. Those drugs now classified as schedule 3 proponents say this is a good change because marijuana shouldn’t be considered a schedule. One drug like heroin. The difference schedule one is a drug considered to have no accepted medical purposes. Schedule. 3 drugs are deemed to have moderate to low potential for physical and psychological dependence. The Ohio cannabis coalition supports the move. In a statement from executive director David boling, he calls this important progress in federal policy and says it brings long overdue tax relief for Ohio businesses.”Video filesFullCompactSort byDateSummaryRelevancePopularityPer page81216Audio filesFullCompactSort byDateSummaryRelevancePopularityPer page81216Recipient e-mailMessage (optional)Preview

Source: Grabien Stories